February 4, 2012
Pharmacy news, jobs, continuing education, community and more.
INDIANAPOLIS, – Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010. Semagacestat is a gamma secretase inhibitor that had been studied as a potential treatment for Alzheimer’s disease. Results shown today provided patient outcomes from [...]
INDIANAPOLIS, Aug 12, 2010 -Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera(R) (atomoxetine). In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly’s ’590 [...]
INDIANAPOLIS, March 17, 2010 - Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14. Lilly is working with the U.S. Food and Drug Administration’s Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases [...]
PARSIPPANY, N.J. and INDIANAPOLIS, March 15, 2010 - A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix(R) (clopidogrel) plus aspirin or Effient(R) (prasugrel) plus aspirin and managed [...]
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension). In [...]
© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.